

Dermatomycoses: Pipeline Intelligence, 2019

https://marketpublishers.com/r/D4A2F2677C8EN.html Date: December 2018 Pages: 60 Price: US\$ 800.00 (Single User License) ID: D4A2F2677C8EN

Abstracts

This report can be delivered to the clients within 1-2 Business Days.

CmaxInsight's, "Dermatomycoses-Pipeline Intelligence, 2019", report provides comprehensive insights about pipeline drugs across this Indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Dermatomycoses.

Highlights and Scope of the Report Indication Overview:

This section of the report provides comprehensive coverage of indication enables the client to understand the landscape of the Dermatomycoses. It covers the basic definition, causes, symptoms, pathophysiology and treatment guidelines for Dermatomycoses disease. The section highlights the symptoms experienced by the patients, and disease progression in patients. The report also summarizes the multiple methods through which the patient can be diagnosed for Dermatomycoses disease.

Pipeline Covered:

This section mentions all the promising therapies in different phases of development including the NDA/BLA Filing, Phase III, Phase II, Phase I, Pre-Clinical and the Discovery. The section also details the products which have been dormant or discontinued during the trial stages of development.

Drug Profiles:

The pipeline guide features provide descriptive drug profiles for the pipeline products which comprise product description, Research and development, and product development activity.



Product description

It comprises of descriptive drug profiles for the pipeline products in terms of its mechanism of action, mode of administration, molecule type, chemical information, etc.

Research and development

This section of the report focusing on the clinical and pre-clinical activity which provide detailed information about the efficacy, safety and tolerability of pipeline drugs. A snapshot on the clinical trial of a pipeline therapy includes information about sponsor, stage of development, trial design, enrollment number, location, study start and primary completion date, and dosage frequency and formulation of the drug.

Product Development Activity

This section of the report provides detail information about licensing and collaboration, funding & financing, designation, patent, technology, key milestones and other developmental activities.

Therapeutic assessment

The report comprises of comparative pipeline therapeutics assessment by stage of development, therapy type, target, molecule type, and route of administration across this indication.

Company profile

Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial

Methodology

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by CmaxInsight's team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.



Reasons to buy

Establish a comprehensive understanding of key competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Discover in licensing and out licensing strategies by identifying potential partners with progressing projects for Dermatomycoses to enhance and expand business potential and scope

Plan mergers and acquisitions successfully by identifying major players with the most promising pipeline therapeutics in the target demographic

Our extensive in-depth analysis on therapy portfolio support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the dormant or discontinued drugs

Develop strategic initiatives by understanding the focus areas of leading companies.

Assess challenges and opportunities that influence Dermatomycoses R&D

Please note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.



Contents

1. REPORT INTRODUCTION

Executive Summary Key findings

2. DERMATOMYCOSES- DISEASE OVERVIEW

3. PIPELINE THERAPEUTICS

An Overview of Pipeline Products for Dermatomycoses

4. COMPARATIVE ANALYSIS OF PIPELINE THERAPEUTICS

5. PRODUCTS IN LAST / MID / EARLY CLINICAL STAGE DEVELOPMENT

5.1 Drug Name: Company NameProduct DescriptionResearch and Development (Clinical and Pre-clinical activity)Product Development ActivitiesKey Development milestone

6. PRODUCTS IN PRE-CLINICAL STAGE DEVELOPMENT

6.1 Drug Name: Company NameProduct DescriptionResearch and Development (Pre-clinical activity)Product Development ActivitiesKey Development milestone

7. PRODUCTS IN DISCOVERY STAGE DEVELOPMENT

7.1 Drug Name: Company NameProduct DescriptionResearch and Development (In-vitro activity)Product Development ActivitiesKey Development milestone



8. THERAPEUTIC ASSESSMENT OF PIPELINE ACTIVE PRODUCTS

Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type Pipeline Assessment by Indication

9. DORMANT / DISCONTINUED PRODUCTS

9.1 Drug Name: Company NameProduct DescriptionResearch and DevelopmentProduct Development ActivitiesReason for dormancy/discontinuation

10. COMPANY PROFILING

Appendix Report Methodology Disclaimer About CmaxInsight Note: Certain sections of the table of contents would vary according to the availability of information



List Of Tables

LIST OF TABLES

Table 1: Total Pipeline Products for Dermatomycoses
Table 2: Number of Products under Development by Companies
Table 3: Late stage Therapeutic Products
Table 4: Mid stage Therapeutic Products
Table 5: Early stage Therapeutic Products
Table 6: Pre-clinical stage Therapeutic Products
Table 7: Discovery stage Therapeutic Products
Table 8: Pipeline Analysis by Route of Administration
Table 9: Pipeline Analysis by Stage and Route of Administration
Table 10: Pipeline Analysis by Stage and Molecule Type
Table 12: Pipeline Analysis by Target
Table 13: Dormant / Discontinued Products
Table 14: Company Profile



List Of Figures

LIST OF FIGURES

- Figure 1: Total Pipeline Products for Dermatomycoses
- Figure 2: Late stage Therapeutic Products
- Figure 3: Mid stage Therapeutic Products
- Figure 4: Early stage Therapeutic Products
- Figure 5: Pre-clinical stage Therapeutic Products
- Figure 6: Discovery stage Therapeutic Products
- Figure 7: Pipeline Analysis by Route of Administration
- Figure 8: Pipeline Analysis by Stage and Route of Administration
- Figure 9: Pipeline Analysis by Molecule Type
- Figure 10: Pipeline Analysis by Stage and Molecule Type
- Figure 11: Pipeline Analysis by Target
- Figure 12: Dormant / Discontinued Products



I would like to order

Product name: Dermatomycoses: Pipeline Intelligence, 2019 Product link: https://marketpublishers.com/r/D4A2F2677C8EN.html Price: US\$ 800.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/D4A2F2677C8EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970